Press Release

Sysmex Announces Establishment of Overseas Subsidiary in Spain to Expand Life Science Business

  Sysmex Corporation (HQ: Kobe, Japan; President: Hisashi Ietsugu) today announced that it established Sysmex Espana S.L. in Barcelona Spain on January 1 2010 to further expand its Life Science business in that country. The company will provide comprehensive sales and after-sales support services for its life science-related products in Spain.

  Sysmex started its life science business in Europe in 2008 ahead of other regions and, has
expanded the business steadily since that time. In Spain sentinel lymph-node
histopathological diagnosis for breast cancer screening is well advanced in Europe and,
Sysmex products have enjoyed a high reputation with contoinuously increasing number of

  Sysmex established Sysmex Espana S.L. to reinforce direct sales and after-sales support
activities for its Life Science products in Spain, thereby accelerating the respective expansion
through an own local presence and the respecive proximity to its clients. By further
promoting the intraoperative diagnosis of sentinel lymph node the company will contribute to
improve diagnostic efficiency and accuracy thus contributing to the patients' quality of life.
  Sysmex will also continue its expansion in Life Science business in other European

[Outline of the new subsidiary]
Name: Sysmex Espana S.L.
Barcelona, Spain
Fernando Andreu
January 1, 2010
Capital supplied by:
Sysmex Europe GmbH
(Sysmex Europe GmbH is a 100% subsidiary of Sysmex Corporation)
7 (FY2009)
Line of business:
Sales and after-sales support for Life Science products in Spain


【Sysmex Life science product】
  It is regarded as desirable to minimize the extent of lymph node dissection in breast cancer
treatment for the patient's quality of life (QOL). At present, the pathology lab offers a
provisional diagnostic of the sentinel lymph node, where the metastasized cancer cells first
reach, intra-operatively and then does a confirmatory study after the surgery to determine
the extent of resection as well as, the post-surgical therapeutic principle. Intra-operative
diagnosis of cancer metastasis requires highly skilled and experienced surgeons. Sysmex's
gene amplification detector RD-100i enables the detection of breast cancer metastases in
sentinel lymph node in approximately 30 minutes, thus facilitating intra-operative diagnosis
to reduce the need for further surgery*. This consequently reduces the burden on patients
while reducing overall case costs. 
  Sysmex is also doing intensive research and development to extend the usage of this
diagnostic principle further into colorectal, gastric and other types of cancer.

  *If any metastasis is detected post-operatively with conventional testing methods, an
additional surgical intervention or other treatment is required.


  • Information contained in the press release is current as of the date of the announcement,
    but may be subject to change without prior notice.

Back to "Press Release"